Imiglucerase is named as a drug or biological intervention in 2 clinical trials in our UK, USA and China trial registers, none of which are currently recruiting. Lead sponsors include Genzyme, a Sanofi Company (1) and Sanofi (1). Registered phases: Phase 2 and Phase 3. Conditions studied include Gaucher Disease Type 1; Gaucher Disease Type 3; Gaucher's Disease Type III.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT05222906 | Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3 Gaucher's Disease Type III |
Phase 3 | Active, closed |
| NCT02843035 | Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension (ClinicalTrials.gov ↗) Gaucher Disease Type 1, Gaucher Disease Type 3 |
Phase 2 | Active, closed |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Gaucher Disease Type 1 | 1 |
| Gaucher Disease Type 3 | 1 |
| Gaucher's Disease Type III | 1 |
| Lead sponsor | Trials |
|---|---|
| Genzyme, a Sanofi Company | 1 |
| Sanofi | 1 |
| Register | Imiglucerase trials |
|---|---|
| Clinical trials in UK | 2 |
| Clinical trials in USA | 2 |
| Clinical trials in China | 1 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Imiglucerase works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Imiglucerase (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.